Schedule 13G ownership disclosure

GT BIOPHARMA INC

Common Stock, par value $0.001 · CUSIP: 36254L308

Event date: 2024-09-30

Filing-level shares
219,457.00
Percent of class
9.8%
  • CYTOVANCE BIOLOGICS INC

    Shares: 219,457.00 · Class: 9.8%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001042167-24-000067
Form type
SCHEDULE 13G/A
Filer
CYTOVANCE BIOLOGICS INC
CIK
CIK 1231100
Filed
Oct 17, 2024
Reporting period
Sep 30, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub